Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis
M. Montemurro, H. Gelderblom, U. Bitz, J. Schütte, J. Y. Blay, H. Joensuu, J. Trent, S. Bauer, P. Rutkowski, F. Duffaud, D. Pink
Fingerprint
Dive into the research topics of 'Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis'. Together they form a unique fingerprint.